CDK 4/6 Inhibitor LEE011 (Ribociclib) in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer
The drug involved in this study is:
Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in combination with Adjuvant endocrine therapy at varying Duration for ER-positive Breast Cancer (LEADER)
- ClinicalTrials.gov Identifier: NCT03285412
- Protocol Number: 17-232
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required